TC Medical(SH:600763) Sou Hu Cai Jing·2026-01-12 12:03Core Viewpoint - Tongce Medical (600763) shows a steady growth in revenue and net profit, indicating a stable performance in the medical services sector [2]. Group 1: Stock Performance - As of January 12, 2026, Tongce Medical's stock closed at 42.34 yuan, up by 1.61%, with a turnover rate of 2.38% and a trading volume of 106,300 lots, resulting in a transaction value of 448 million yuan [1]. - On January 12, the net inflow of main funds was 22.82 million yuan, accounting for 5.09% of the total transaction value, while retail investors saw a net outflow of 21.28 million yuan, representing 4.75% of the total transaction value [1]. Group 2: Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year, and a net profit attributable to shareholders of 514 million yuan, up by 3.16% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, and a net profit of 192 million yuan, which is a 2.31% increase year-on-year [2]. - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while the gross profit margin is reported at 41.69% [2]. Group 3: Analyst Ratings - In the last 90 days, seven institutions have provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2]. - The average target price set by institutions over the past 90 days is 5.29 billion yuan [2].